A major breakthrough in the treatment of Hepatitis B has offered fresh hope to millions of people worldwide. New clinical trials of an experimental drug called bepirovirsen have shown that around 20% of patients achieved a functional cure when the treatment was combined with standard antiviral therapy. The findings were recently published in the prestigious New England Journal of Medicine and presented at one of Europe’s largest liver health conferences.
A Significant Step Forward in Liver Disease Treatment
Hepatitis B remains one of the leading causes of chronic liver disease and liver cancer globally, affecting more than 240 million people. India carries a particularly heavy burden, accounting for a significant share of the world’s hepatitis B cases and liver-related deaths.
The latest research marks one of the most encouraging developments in decades of efforts to find an effective cure for the disease.
What Is a Functional Cure?
A functional cure does not completely eliminate the virus from the body. Instead, it allows patients to naturally control the infection without requiring ongoing treatment.
Unlike some viral infections, Hepatitis B integrates itself into a person’s genetic material, making complete eradication extremely difficult. Even after successful treatment, traces of the virus can remain dormant and potentially reactivate if the immune system becomes weakened.
How the New Drug Works
The experimental drug, bepirovirsen, was administered alongside standard antiviral medication for six months. Researchers found that about one in five participants achieved a functional cure and were able to maintain control over the virus even after stopping treatment.
Patients were considered successfully treated only if they remained virus-free for at least 24 weeks after discontinuing all medication.
Experts Call It a Milestone
According to liver specialist Cyriac Abby Philips, popularly known as “The Liver Doctor,” the trial represents a major scientific achievement because it is the first large Phase 3 study designed specifically to achieve a functional cure as its primary objective.
However, he cautioned that the treatment currently appears most effective for a limited group of patients, particularly those who have already been diagnosed, are receiving antiviral therapy, have low viral antigen levels, and do not have advanced liver damage such as cirrhosis.
Challenges Still Remain
While the results are encouraging, experts emphasize that the treatment is not a permanent cure. Current data only confirms that patients remained virus-free for about six months after stopping therapy.
Researchers still need long-term data to determine whether the benefits will last three, five, or even ten years. There is also a possibility that viral markers could return over time.
Importance of Early Testing
Doctors stress that the biggest challenge remains diagnosis rather than treatment. Millions of people with Hepatitis B are unaware they are infected because symptoms may not appear for years.
Health experts recommend that everyone get tested for Hepatitis B at least once during their lifetime, especially individuals with risk factors such as exposure to infected blood, unprotected sexual contact, or a family history of the disease.
Continued Monitoring Is Essential
Even for patients who achieve a functional cure, regular medical follow-up remains critical. The risk of liver complications, including liver cancer, does not disappear completely, and ongoing surveillance is necessary to ensure long-term health.
While the new findings represent a promising advance in Hepatitis B treatment, researchers agree that further studies are needed before the therapy can be considered a long-term solution for the millions living with the disease worldwide.